Nina S. Kjellson - 17 Sep 2021 Form 4/A - Amendment Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Director
Signature
/s/ John Healy, Attorney-in Fact
Issuer symbol
TYRA
Transactions as of
17 Sep 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
20 Sep 2021, 18:36:16 UTC
Date Of Original Report
17 Sep 2021
Previous filing
14 Sep 2021
Next filing
15 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Conversion of derivative security +3,936,595 3,936,595 17 Sep 2021 By Canaan XI L.P. F1, F2
transaction TYRA Common Stock Conversion of derivative security +473,396 473,396 17 Sep 2021 By 2020+ Co-Investment L.P. - Series 7 F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Series A Preferred Stock Conversion of derivative security $0 -1,333,334 -100% $0.000000* 0 17 Sep 2021 Common Stock 3,463,201 By Canaan XI L.P. F1, F2
transaction TYRA Series B Preferred Stock Conversion of derivative security $0 -182,257 -100% $0.000000* 0 17 Sep 2021 Common Stock 473,394 By Canaan XI L.P. F1, F2
transaction TYRA Series B Preferred Stock Conversion of derivative security $0 -182,258 -100% $0.000000* 0 17 Sep 2021 Common Stock 473,396 By 2020+ Co-Investment L.P. - Series 7 F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2 The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.
F3 The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

Remarks:

This amendment is being filed in order to amend the number of shares reflected in Table I, Column 5, Row 1 relating to the conversion of Common Stock on 9/17/2021. The information reported in the original Form 4, filed with the Securities & Exchange Commission on September 17, 2021, is otherwise correct in all respects.